POLYCYSTIC KIDNEY DISEASE-TOLVAPTAN
From NeuroRehab.wiki
Revision as of 11:48, 31 January 2023 by Dr Appukutty Manickam (talk | contribs) (Imported from text file)
SUMMARY
1. Blocks V2 receptors in distal nephron and collection duct. In PCKD: reduce cysts formation.
2. Prevents the binding of vasopressin, reduce expression of aquaporins.
3. Promotes water excretion: polyuria and potential dehydration.
4. Important to maintain adequate hydration to prevent activation of V1 receptors.
Reference(s)
Wilkinson, I. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
